Phase 3 Trials for Antiamyloid Gantenerumab Show Poor Results.

Published Date: 25 Nov 2023

The antiamyloid monoclonal antibody gantenerumab reduced the burden of amyloid plaque in early-stage Alzheimer's disease patients, but there was no discernible cognitive benefit in twin pivotal trials.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot